Publication

Bacterial Translocation and Risk of Liver Cancer in a Finnish Cohort

Downloadable Content

Persistent URL
Last modified
  • 05/14/2025
Type of Material
Authors
    Baiyu Yang, Stanford UniversityJessica L. Petrick, National Cancer InstituteJake E. Thistle, National Cancer InstituteLigia A. Pinto, National Cancer InstituteTroy J. Kemp, Leidos Biomedical Research, Inc.Quang Tan Hao, Georgia State UniversityAndrew Gewirtz, Emory UniversityTim Waterboer, German Cancer Research CenterVeronika Fedirko, Emory UniversityMazda Jenab, International Agency for Research on CancerBarry L. Graubard, National Cancer InstituteStephanie J. Weinstein, National Cancer InstituteDemetrius Albanes, National Cancer InstituteKatherine A. McGlynn, National Cancer Institute
Language
  • English
Date
  • 2019-04-01
Publisher
  • American Association of Cancer Research
Publication Version
Copyright Statement
  • © 2019 by the American Association for Cancer Research.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 28
Issue
  • 4
Start Page
  • 807
End Page
  • 813
Grant/Funding Information
  • This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health under Z01-CP010158-18.
Supplemental Material (URL)
Abstract
  • Background: Elevated systemic exposure to gut-derived bacterial products has been associated with hepatic inflammation and chronic liver diseases, potentially increasing the risk of liver cancer. However, only one prior study prospectively examined exposure to bacterial products in the circulation and risk of liver cancer, with a relatively limited coverage of biomarkers. Methods: We conducted a nested case-control study (224 liver cancer cases and 224 matched controls) in a large cohort of Finnish male smokers followed from baseline (1985-1988) to 2014. The associations between a panel of biomarkers for bacterial translocation and the risk of liver cancer were assessed using multivariable-adjusted conditional logistic regression. The biomarkers included immunoglobulin (Ig) A, IgG, and IgM against lipopolysaccharide (LPS) and flagellin, soluble CD14 (an LPS co-receptor), and the LPS-binding protein. Results: Anti-flagellin IgA (OR=2.79 (95% CI=1.34-5.78, ptrend=0.01) and anti-LPS IgA 2.44 (95% CI=1.33-4.48, ptrend<0.01), were significantly associated with risk of liver cancer. When restricting the analysis to histologically-classified hepatocellular carcinoma, the ORs were 4.18 (95% CI=1.60-10.92, ptrend<0.01) and 2.48 (95% CI=1.16-5.29, ptrend<0.01), respectively. The results were not substantially changed after excluding cases diagnosed within the first five years of follow-up and those with hepatitis C virus infection. Conclusions: Antibodies to flagellin and LPS were associated with increased risk of liver cancer. Impact: Gut-derived bacterial translocation into the circulation may play a role in the development of primary liver cancer. Our findings could contribute to the understanding of primary liver cancer etiology and further prevention efforts.
Author Notes
  • Correspondence: Dr. Katherine A. McGlynn, Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Room 6E-446 Bethesda, MD 20892-9774, United States. Phone: 240-276-7297. Fax: 240-276-7838. mcglynnk@mail.nih.gov
Keywords
Research Categories
  • Health Sciences, Oncology
  • Health Sciences, Epidemiology
  • Health Sciences, Public Health
  • Health Sciences, Immunology

Tools

Relations

In Collection:

Items